NCT03726749View on ClinicalTrials.gov

Tocilizumab Plus a Short Prednisone Taper for GCA

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

December 15, 2021

Study Completion Date

December 29, 2021

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab

Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor

DRUG

Prednisone

Prednisone is an anti-inflammatory medication

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Roche-Genentech

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03726749 - Tocilizumab Plus a Short Prednisone Taper for GCA | Biotech Hunter | Biotech Hunter